Adam JacksonFebruary 11, 2025
Cybin pushes forward with Phase 3 depression trials after narrowing its loss, while securing a $100M funding program.
Tag: Cybin
Adam JacksonFebruary 11, 2025
StaffMarch 13, 2024
The Daily Hit is a recap of the top financial news stories for March 13, 2024. On the Site Ascend CEO shares details on 280E tax nullification strategy In the wake of Ascend’s annual earnings filing this week, CEO John Hartmann again sat down with Green Market Report to talk about the highlights, including the company’s new tax […]
John SchroyerMarch 13, 2024
Toronto-based Cybin Inc. (NYSE:CYBN) will be raising roughly $150 million through the private placement of more than 348 million common shares to continue funding operations and clinical trials, the company announced Wednesday. A psychedelics firm that is still in the pre-revenue stage, the proceeds from the raise will be used to support “certain Phase 3 […]
StaffFebruary 14, 2024The Daily Hit is a recap of the top financial news stories for Feb. 14, 2024. On the Site California attorney found social equity partners just weeks before suing New York A Southern California attorney who is asking a federal court to again freeze New York’s cannabis licensing admitted in a new court filing on Valentine’s […]
StaffOctober 25, 2023
The Daily Hit is a recap of the top financial news stories for Oct. 25, 2023. On the Site New Mexico Pursues Unpaid Taxes From Cannabis Companies More than 100 marijuana license holders in New Mexico were delinquent on their state taxes, leading to an enforcement push, the state Department of Taxation and Revenue announced […]
Adam JacksonSeptember 27, 2023
The DMT drug appeared more effective when combined with SSRIs.
Adam JacksonSeptember 6, 2023Preliminary DMT therapy data will guide the decision to initiate a phase 2 trial in the U.S. in early 2024.
Adam JacksonAugust 29, 2023
Cybin and Small Pharma holders will own around 74.5% and 25.5% of the combined company, respectively.
John SchroyerAugust 14, 2023
Toronto-based Cybin Inc. (NYSE: CYBN) (NEO: CYBN) increased its losses for its first fiscal quarter of 2023 to C$14.5 million, up from C$13.1 million a year prior, but company leadership remained bullish that it’s on the right path to gain federal approval in the U.S. for its psychedelic mental health treatments. Cybin continued investing in […]
Debra BorchardtJuly 12, 2023
Cybin noted that the new codes create a clearer path for insurance reimbursement.
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.